Working... Menu

Personalize my Treatment

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02355171
Recruitment Status : Recruiting
First Posted : February 4, 2015
Last Update Posted : June 1, 2018
Information provided by (Responsible Party):
Exactis Innovation

Brief Summary:
The 'Personalize My treatment' (PMT) platform is a novel form of biobanking in which cancer patients willingly consent to provide residual, clinical samples (surplus after diagnostic testing) of their tumors for cancer research, to give access to their medical record for data collection and then followed prospectively throughout the trajectory of their illness. They further willingly consent to be recontacted for being informed of other research projects, including clinical trials.

Condition or disease

Layout table for study information
Study Type : Observational
Estimated Enrollment : 10000 participants
Observational Model: Cohort
Time Perspective: Other
Official Title: A Large-scale Longitudinal Oncology Platform
Study Start Date : November 2015
Estimated Primary Completion Date : March 2019

Primary Outcome Measures :
  1. The primary objective of PMT is to create a collection of cancer patient biospecimens and annotated data that will be used for clinical trial matching and to advance cancer research. [ Time Frame: Longitudinal ]

Biospecimen Retention:   Samples With DNA
Tissue (from surgical resection or biopsy) and blood

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with breast, ovarian, lung, skin, colorectal and/or prostate cancer treated in a hospital in Canada.
Age of majority in the province of recruitment.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02355171

Layout table for location contacts
Contact: Jackie Girgis, MSc 514-282-4523 ext 218
Contact: Camille Le Sourd, MSc 514-282-4523 ext 219

Layout table for location information
Canada, Alberta
Tom Baker Cancer Centre Recruiting
Calgary, Alberta, Canada, T2N 4N2
Contact: Sonali Deshpande   
Principal Investigator: Gwyn Bebb, MD         
Canada, New Brunswick
Centre hospitalier universitaire Dr-Georges-L.-Dumont Recruiting
Moncton, New Brunswick, Canada, E1C 2Z3
Contact: Stéphanie Crapoulet    506-862-4221      
Principal Investigator: Eve St-Hilaire, MD         
The Moncton Hospital Recruiting
Moncton, New Brunswick, Canada, E1C 6Z8
Contact: Ian Chute, MSc   
Contact: Jordan Kennedy, BSc   
Principal Investigator: Mahmoud Abdelsalam, MD         
Canada, Ontario
The Ottawa Hospital Recruiting
Ottawa, Ontario, Canada, K1H 8L6
Contact: Elina Iordanidi   
Principal Investigator: John Hilton, MD         
Odette Cancer Centre - Sunnybrook Hospital Recruiting
Toronto, Ontario, Canada, M4N 3M5
Contact: Mark Gichuru   
Principal Investigator: Helen MacKay, MD         
Canada, Quebec
Centre hospitalier de l'Université de Montréal Recruiting
Montreal, Quebec, Canada, H2X 0A9
Contact: Renée Bernatchez   
Principal Investigator: Fred Saad, MD         
Jewish General Hospital Recruiting
Montreal, Quebec, Canada, H3T 1E2
Contact: Fredrick Charbonneau, MSc   
Contact: Urszula Krzemien, MSc   
Principal Investigator: Mark Basik, MD         
Centre hospitalier universitaire de Québec - Université Laval Recruiting
Québec, Quebec, Canada, H3T 1Y6
Contact: Jean-Charles Hogue, PhD   
Principal Investigator: Louise Provencher, MD         
Centre hospitalier universitaire de Sherbrooke Recruiting
Sherbrooke, Quebec, Canada, J1G 2E8
Contact: Noémie Poirier   
Contact: Suzanne Maltais   
Principal Investigator: Julie Carrier, MD         
CIUSSS de la Mauricie-et-du-Centre-du-Québec - Centre Hospital Régional Recruiting
Trois-Rivières, Quebec, Canada, G8Z 3R9
Contact: Marie-Eve Caron   
Contact: Vanessa Gagné   
Principal Investigator: Francois Vincent, MD         
Sponsors and Collaborators
Exactis Innovation

Additional Information:
Layout table for additonal information
Responsible Party: Exactis Innovation Identifier: NCT02355171     History of Changes
Other Study ID Numbers: PMT
First Posted: February 4, 2015    Key Record Dates
Last Update Posted: June 1, 2018
Last Verified: May 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: The BDAC (Biospecimen and Data Access Committee) authorizes access requests from researchers to the PMT Platform's biospecimens and data. It meets as needed to review requests in accordance with the PMT Biospecimen and Data Access Policy. Requests will be evaluated based on scientific merit, availability of sample and alignment with the mission of the PMT Platform and Exactis. BDAC is responsible for verifying that the proposed project has received appropriate ethics approval and proof of such approval has been provided.